Tissue inhibitor metalloproteinase-2 (TIMP-2) IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI

Journal of the American Society of Nephrology

Volumn 26, Issue 7, 2015, Pages 1747-1754

  Koyner, Jay L ^a   Shaw, Andrew D ^b   Chawla, Lakhmir S ^c   Hoste, Eric A J ^d   Bihorac, Azra ^e   Kashani, Kianoush ^f   Haase, Michael ^g   Shi, Jing ^h   Kellum, John A ⁱ  

^a UNIVERSITY OF CHICAGO   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g OTTO VON GUERICKE UNIVERSITY   (Germany)

^h Statistics at Walker BioSciences   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SOMATOMEDIN BINDING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1;

ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; DIALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; ACUTE KIDNEY INJURY; COHORT ANALYSIS; COMPARATIVE STUDY; FOLLOW UP; HEMODIALYSIS; KAPLAN MEIER METHOD; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME; URINE;

ACUTE KIDNEY INJURY; ADULT; BIOMARKERS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; KAPLAN-MEIER ESTIMATE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME;

EID: 84934759130     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014060556     Document Type: Article

References (35)

1. Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, Shlipak MG, Parikh CR; TRIBE-AKI Consortium: Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J AmSoc Nephrol 25: 1063-1071, 2014
2. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR: Long-term risk of mortality and other adverse outcomes after acute kidney injury: A systematic review and meta-analysis. AmJ Kidney Dis 53: 961-973, 2009
3. Bagshaw SM, Mortis G, Doig CJ, Godinez-Luna T, Fick GH, Laupland KB: One-year mortality in critically ill patients by severity of kidney dysfunction: Apopulation-based assessment.AmJ KidneyDis 48: 402-409, 2006
4. Chertow GM, Christiansen CL, Cleary PD, Munro C, Lazarus JM: Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 155: 1505-1511, 1995
5. Morgera S, Kraft AK, Siebert G, Luft FC, Neumayer HH: Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis 40: 275-279, 2002
6. Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A: Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 119: 2444-2453, 2009
7. Bihorac A, Yavas S, Subbiah S, Hobson CE, Schold JD, Gabrielli A, Layon AJ, SegalMS: Long-termrisk ofmortality and acute kidney injury during hospitalization after major surgery. Ann Surg 249: 851-858, 2009
8. Koyner JL, Parikh CR: Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J Am Soc Nephrol 8: 1034-1042, 2013
9. Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, Fitzgerald R, GongMN,GrahamDD, Gunnerson K, HeungM, Jortani S, Kleerup E, Koyner JL, Krell K, Letourneau J, Lissauer M, Miner J, Nguyen HB,Ortega LM, SelfWH, Sellman R, Shi J, Straseski J, Szalados JE, Wilber ST, Walker MG, Wilson J, Wunderink R, Zimmerman J, Kellum JA: Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 189: 932-939, 2014
10. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM, Chawla LS, Davison DL, Feldkamp T, Forni LG, Gong MN, Gunnerson KJ, Haase M, Hackett J, Honore PM, Hoste EA, Joannes-Boyau O, Joannidis M, Kim P, Koyner JL, Laskowitz DT, Lissauer ME, Marx G, McCullough PA, Mullaney S, Ostermann M, Rimmelé T, Shapiro NI, Shaw AD, Shi J, Sprague AM, Vincent JL, Vinsonneau C, Wagner L, Walker MG, Wilkerson RG, Zacharowski K, Kellum JA: Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17: R25, 2013
11. Akcay AB,Ozlu MF, SenN, Cay S,OzturkOH, Yalcn F, Bilen P, Kanat S, Karakas MF, Isleyen A, Demir AD, Sogut S, Covic A, Kanbay M: Prognostic significance of neutrophil gelatinase-associated lipocalin in ST-segment elevation myocardial infarction. J Investig Med 60: 508-513, 2012
12. Aregger F, Uehlinger DE, Witowski J, Brunisholz RA, Hunziker P, Frey FJ, Jorres A: Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. Kidney Int 85: 909-919, 2014
13. Severino V, AlessioN, Farina A, Sandomenico A, CipollaroM, Peluso G, Galderisi U, Chambery A: Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell Death Dis 4: e911, 2013
14. Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C, Seth A: IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat 133: 563-573, 2012
15. Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Umeshita K, Kim T, Wakasa K, Doki Y, Mori M, Nagano H: IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer 130: 319-327, 2012
16. Musiał K, Zwolinska D: The sFas/sFasL ratio as a novel marker of inflammation in childrenwith chronic kidney disease. Clin Chim Acta 414: 7-11, 2012
17. Miya M, Maeshima A, Mishima K, Sakurai N, Ikeuchi H, Kuroiwa T, Hiromura K, Yokoo H, Nojima Y: Enhancement of in vitro human tubulogenesis by endothelial cell-derived factors: Implications for in vivo tubular regeneration after injury. Am J Physiol Renal Physiol 301: F387-F395, 2011
18. Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG: Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 281: 3711-3721, 2006
19. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG: TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 114: 171-180, 2003
20. Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: Metalloproteinase-independent biological activities. Sci Signal 1: re6, 2008
21. Wajapeyee N, Serra RW, Zhu X,MahalingamM, GreenMR:Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374, 2008
22. Zuo S, Liu C, Wang J, Wang F, Xu W, Cui S, Yuan L, Chen X, Fan W, Cui M, Song G: IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 138: 1045-1055, 2012
23. Hodeify R, Tarcsafalvi A, Megyesi J, Safirstein RL, Price PM: Cdk2-dependent phosphorylation of p21 regulates the role of Cdk2 in cisplatin cytotoxicity. Am J Physiol Renal Physiol 300: F1171-F1179, 2011
24. Price PM, Safirstein RL, Megyesi J: The cell cycle and acute kidney injury. Kidney Int 76: 604-613, 2009
25. Yu F, Megyesi J, Safirstein RL, Price PM: Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am J Physiol Renal Physiol 289: F514-F520, 2005
26. Wang Z, Famulski K, Lee J, Das SK,Wang X,Halloran P, Oudit GY, Kassiri Z: TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury. Kidney Int 85: 82-93, 2014
27. Cavdar Z, Oktay G, Egrilmez MY, Genc S, Genc K, Altun Z, Islekel H, Guner G: In vitro reoxygenation following hypoxia increases MMP-2 and TIMP-2 secretion by human umbilical vein endothelial cells. Acta Biochim Pol 57: 69-73, 2010
28. Rüster C,Wolf G: Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 22: 1189-1199, 2011
29. Ruiz-OrtegaM, LorenzoO, Suzuki Y,Rupérez M,Egido J: Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001
30. Faubel S, Chawla LS, Chertow GM, Goldstein SL, Jaber BL, Liu KD; Acute Kidney Injury Advisory Group of the American Society of Nephrology: Ongoing clinical trials in AKI. Clin J Am Soc Nephrol 7: 861-873, 2012
31. KDIGO: Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int [Suppl 2]: 19-33, 2012
32. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
33. Pencina MJ, D'Agostino RB Sr., Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30: 11-21, 2011
34. Chambless LE, Cummiskey CP, Cui G: Several methods to assess improvement in risk predictionmodels: Extension to survival analysis. Stat Med 30: 22-38, 2011
35. R Development Core Team: R: A Language and Environment for Statistical Computing, Vienna, Austria, R Foundation for Statistical Computing, 2008